Center-Authored Papers

Filters: Author is Maloney, David  [Clear All Filters]
Journal Article
Matesan M, Rajendran J, Press OW, Maloney DG, Storb RF, Cassaday RD, Pagel JM, Oliveira G, Gopal AK.  2014.  90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution.. Nuclear medicine communications. 35(11):1132-42. Abstract
Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG, Matesan MC, Storb R, Press OW.  2011.  90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.. Blood. 118(4):1132-9. Abstract
Gardner R, Wu D, Cherian S, Fang M, Hanafi L-A, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG et al..  2016.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.. Blood. 127(20):2406-2410. Abstract
Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ.  2014.  Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.. Cancer journal (Sudbury, Mass.). 20(2):141-4. Abstract
Bensinger WI, Rotta M, Storer B, Chauncey T, Holmberg L, Becker P, Sandmaier BM, Storb R, Maloney D.  2012.  Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center.. Bone marrow transplantation. 47(10):1312-7. Abstract
Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, McSweeney P, Niederwieser D, Bruno B, Storb R et al..  2010.  Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.. British journal of haematology. 150(2):170-8. Abstract
Shadman M, Hingorani S, Lanum SA, Pagel JM, Storb R, Maloney DG, Sandmaier BM.  2016.  Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis - a single institution experience.. Leukemia & lymphoma. :1-3.
Storb R, Gyurkocza B, Storer BE, Maloney DG, Sorror ML, Mielcarek M, Martin PJ, Sandmaier BM.  2013.  Allogeneic Hematopoietic Cell Transplantation Following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(5):792-8. Abstract
Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, Hale GA, Maharaj D, Gale RP, Rowlings PA et al..  2014.  Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome.. Bone marrow transplantation. Abstract
Zimmerman Z, Scott BL, Gopal AK, Sandmaier BM, Maloney DG, Deeg HJ.  2012.  Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.. Bone marrow transplantation. 47(6):804-9. Abstract
Bachanova V, Burns LJ, Wang T, Carreras J, Gale RP, Wiernik PH, Ballen KK, Wirk B, Munker R, Rizzieri DA et al..  2015.  Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.. Bone marrow transplantation. 50(2):197-203. Abstract
Maloney DG.  2012.  Anti-CD20 antibody therapy for B-cell lymphomas.. The New England journal of medicine. 366(21):2008-16.
Ram R, Storer BE, Mielcarek M, Sandmaier BM, Maloney DG, Martin PJ, Flowers MED, Chua BK, Rotta M, Storb R.  2012.  Association between Calcineurin Inhibitor Blood Concentrations and Outcomes after Allogeneic Hematopoietic Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(3):414-422. Abstract
Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO et al..  2012.  Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
Maziarz RT, Wang Z, Zhang M-J, Bolwell BJ, Chen AI, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM et al..  2013.  Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.. British journal of haematology. 162(5):648-56. Abstract
Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E, Antin JH, Comenzo R, Goodman S, Hari P et al..  2011.  Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.. The lancet oncology. Abstract
Fenske TS, Zhang M-J, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M et al..  2014.  Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(4):273-81. Abstract
Gutierrez-Delgado F, Maloney DG, Press OW, Golden J, Holmberg LA, Maziarz RT, Hooper H, Buckner CD, Appelbaum FR, Bensinger WI.  2001.  Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens.. Bone marrow transplantation. 28(5):455-61. Abstract
Phipps C, Gopal AK, Storer BE, Cassaday RD, Press OW, Till BG, Pagel JM, Palanca-Wessels MC, Philip M, Bensinger WI et al..  2015.  Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.. Leukemia & lymphoma. 56(1):92-6. Abstract
Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang W-C, Greisman HA et al..  2010.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.. Blood. 116(22):4532-41. Abstract
Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH et al..  2016.  Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.. Journal of the National Cancer Institute. 108(12) Abstract
Onishi M, Graf SA, Holmberg L, Behnia S, Shustov AR, Schiavo K, Philip M, Libby EN, Cassaday RD, Pagel JM et al..  2015.  Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.. Hematological oncology. 33(4):187-191. Abstract
Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM et al..  2016.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.. The Journal of clinical investigation. 126(6):2123-38. Abstract
Turtle CJ, Riddell SR, Maloney DG.  2016.  CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.. Clinical pharmacology and therapeutics. 100(3):252-8. Abstract
Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE et al..  2012.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.. Blood. 119(17):3940-50. Abstract